Results 11 to 20 of about 9,749 (194)

Clinical-economic impact of the change of protocol for use of basiliximab in liver transplant [PDF]

Farmacia Hospitalaria, 2019
Objective: Evaluation of the clinical and economic impact after the protocol change of basiliximab use in orthohepatic transplant. Method: Retrospective study in which all liver transplant patients were included during the years 2013, 2014 and until ...
Enrique Tévar-Alfonso , Inmaculada Plasencia-García , Antonio González- Rodríguez , Antonia Moreno-García , Javier Merino-Alonso , Armando Aguirre- Jaime   +5 more
doaj   +3 more sources

Basiliximab induction therapy in kidney transplantation: Benefits for long term allograft function after 10 years?

Biologics: Targets & Therapy, 2009
Martina Koch, Thomas Becker, Rainer Lueck, Michael Neipp, Juergen Klempnauer, Bjoern NashanKlinik fuer Allgemein-, Viszeral- und Transplantationschirurgie, Medizinische Hochschule Hannover, Hannover, GermanyAbstract: The interleukin-2 receptor antagonist
Martina Koch, Thomas Becker, Rainer Lueck, Michael Neipp, Juergen Klempnauer, Bjoern Nashan   +5 more
doaj   +1 more source

The role of basiliximab in the evolving renal transplantation immunosuppression protocol

Biologics: Targets & Therapy, 2008
Paola Salis, Chiara Caccamo, Roberto Verzaro, Salvatore Gruttadauria, Mary ArteroDivision of Nephrology and Division of Abdominal Transplantation, Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione, Palermo, ItalyAbstract ...
Paola Salis, Chiara Caccamo, Roberto Verzaro, Salvatore Gruttadauria, Mary Artero   +4 more
doaj   +1 more source

Efficacy and safety of basiliximab as initial immunosuppression in liver transplantation: A single center study

Annals of Hepatology, 2020
Introduction and aim: The interleukin-2 receptor antagonist; basiliximab is used to allow delayed introduction of Calcineurin inhibitors (CNI) after liver transplantation and thus delay their renal insult.
Mohamed Hashim, Ayman Alsebaey, Amr Ragab, Hossam Eldeen Soliman, Imam Waked   +4 more
doaj   +2 more sources

Anti-thymocyte globulin versus basiliximab induction in renal transplant recipients: Long-term outcome

Saudi Journal of Kidney Diseases and Transplantation, 2014
Although basiliximab and rabbit anti-thymocyte globulin (ATG) are effective in delaying and reducing the incidence of acute rejection (AR) thus improving short-term graft survival, their impact on long-term graft survival has not been well established in
Sailaja Kesiraju, Purna Paritala, Uma Maheswara Rao Ch, Srinivasa Murthy Athmakuri, V S Reddy, S Sahariah   +5 more
doaj   +2 more sources

Double-blind comparison of hepatitis C histological recurrence Rate in HCV+ Liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine [PDF]

, 2004
BACKGROUND: Hepatitis C virus (HCV) recurrence in HCV+ liver transplant recipients is almost inevitable and may be promoted by immunosuppression. We compared the amount of liver damage with regard to usage of steroids and basiliximab. METHODS: A total of
AGNES S, ROSSI, MASSIMO, CALLEA F, FASSATI LR, FILIPPONI F, VALENTE U, RISALITI A, Agnes, Salvatore, RISALITI, Andrea, FILIPPONI, FRANCO, PISATI R., FERRARA R, BURRA P, GRAZI GL, DE CARLIS L, GRAZI, GIAN LUCA, SALIZZONI M, BURRA, PATRIZIA, Salizzoni, Mauro, ROSSI M   +19 more
core   +3 more sources

The comparative efficacy and safety of basiliximab and antithymocyte globulin in deceased donor kidney transplantation: a multicenter cohort study [PDF]

Kidney Research and Clinical Practice, 2023
Background Generally, an induction agent is chosen based on the conditions of the deceased donor and the recipient. Antithymocyte globulin (ATG) is preferred in relatively high-risk conditions.
Su Yeon Hong, Young Soo Kim, Kyubok Jin, Seungyeup Han, Chul Woo Yang, Byung Ha Chung, Woo Yeong Park   +6 more
doaj   +1 more source

Factors associated with cardiovascular events after simultaneous liver–kidney transplant from the US Multicenter Simultaneous Liver–Kidney Transplant Consortium

Hepatology Communications, EarlyView., 2022
Abstract Cardiovascular disease is a leading complication after both liver and kidney transplantation. Factors associated with and rates of cardiovascular events (CVEs) after simultaneous liver–kidney transplant (SLKT) are unknown. This was a retrospective cohort study of adult SLKT recipients between 2002 and 2017 at six centers in six United Network ...
Jennifer Jo, Gonzalo Crespo, Dyanna Gregory, Jasmine Sinha, Jiaheng Xie, Min Zhang, John Magee, Pranab Barman, Yuval A. Patel, Aaron Schluger, Kara Walters, Scott Biggins, Natalia Filipek, Giuseppe Cullaro, Randi Wong, Jennifer C. Lai, Gabriel J. Perreault, Elizabeth C. Verna, Pratima Sharma, Lisa B. VanWagner   +19 more
wiley   +1 more source

Viability assessment and transplantation of fatty liver grafts using end‐ischemic normothermic machine perfusion

Liver Transplantation, EarlyView., 2022
Abstract End‐ischemic viability testing by normothermic machine perfusion (NMP) represents an effective strategy to recover liver grafts having initially been discarded for liver transplantation (LT). However, its results in the setting of significant (≥30%) macrovesicular steatosis (MaS) have not been specifically assessed.
Damiano Patrono, Riccardo De Carlis, Alessandro Gambella, Francesca Farnesi, Alice Podestà, Andrea Lauterio, Francesco Tandoi, Luciano De Carlis, Renato Romagnoli   +8 more
wiley   +1 more source

Lower dose of ATG combined with basiliximab for haploidentical hematopoietic stem cell transplantation is associated with effective control of GVHD and less CMV viremia

Frontiers in Immunology, 2022
Currently, the graft-versus-host disease (GVHD) prophylaxis consists of an immunosuppressive therapy mainly based on antithymocyte globulin (ATG) or post-transplant cyclophosphamide (PTCy).
Zhenli Huang, Han Yan, Yao Teng, Wei Shi, Linghui Xia   +4 more
doaj   +1 more source